Current Hypertension Reports

, Volume 6, Issue 5, pp 369–376

Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease

Authors

  • Niels H. Andersen
    • Department of Internal Medicine, Diabetes & Endocrinology, Aarhus HospitalAarhus University Hospital
  • Carl E. Mogensen
    • Department of Internal Medicine, Diabetes & Endocrinology, Aarhus HospitalAarhus University Hospital
Article

DOI: 10.1007/s11906-004-0056-y

Cite this article as:
Andersen, N.H. & Mogensen, C.E. Current Science Inc (2004) 6: 369. doi:10.1007/s11906-004-0056-y
  • 31 Views

Abstract

Dual blockade of the renin angiotensin system is based on a principle of obtaining the broadest and most efficient blockade of the effects of angiotensin II, by using the combination of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II-receptor blocker (ARB). By combining two, different pharmacologic principles and inhibiting both the ACE and the angiotensin II type 1 receptor, it seems possible to block both the production and the action of angiotensin II, which would serve as efficient antihypertensive therapy. Exploring the beneficial effects of dualblockade therapy is a work in rapid progress, in both diabetic and non-diabetic nephropathy. But evidence is also emerging in cardiovascular medicine, an overview of which is provided in this article.

Copyright information

© Current Science Inc. 2004